The drug, once projected to compete with Bristol Myers Squibb’s Cobenfy, is from AbbVie’s $8.7 billion acquisition of Cerevel Therapeutics. Cerevel Therapeutics drug tavapadon met the main and ...
In a regulatory filing, AbbVie (ABBV) stated, “On January 9, 2025, AbbVie determined that it will record an impairment charge related to the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback